{"id":3353,"date":"2010-09-17T14:51:26","date_gmt":"2010-09-17T18:51:26","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=3353"},"modified":"2011-07-19T17:44:48","modified_gmt":"2011-07-19T21:44:48","slug":"fda-announces-safety-review-of-pioglitazone","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/09\/17\/fda-announces-safety-review-of-pioglitazone\/","title":{"rendered":"FDA Announces Safety Review of Pioglitazone"},"content":{"rendered":"<p><a href=\"http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm226214.htm\">The FDA announced today<\/a> that it was undertaking a safety review of pioglitazone (Actos). The review was initiated after the FDA received data from Takeda, the drug&#8217;s manufacturer, suggesting a possible increase in bladder cancer in patients taking the drug for more than 2 years. The data are taken from a planned 5-year analysis of an ongoing 10-year epidemiological study designed to examine the association of the drug with bladder cancer, following earlier studies suggesting a possible risk. Although the current analysis found no overall association between pioglitazone and bladder cancer, a further analysis found an increased risk of bladder cancer in those taking the highest cumulative doses of the drug and in those with the longer exposure to the drug.<\/p>\n<p>The FDA said it has not yet concluded that piolglitazone increases the risk of bladder cancer and advised healthcare professionals to continue to follow the recommendation in the drug label.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA announced today that it was undertaking a safety review of pioglitazone (Actos). The review was initiated after the FDA received data from Takeda, the drug&#8217;s manufacturer, suggesting a possible increase in bladder cancer in patients taking the drug for more than 2 years. The data are taken from a planned 5-year analysis of [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[416,196,415,417],"class_list":["post-3353","post","type-post","status-publish","format-standard","hentry","category-prevention","tag-cancer","tag-fda","tag-pioglitazone","tag-safety-review"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/3353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=3353"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/3353\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=3353"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=3353"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=3353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}